Healthcare / Medical DevicesHKSE
$20.24
+0.20 (+1.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-92.5M · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.8B
P/E
23.3x
↑EV/EBITDA
45.0x
↑ROE
3.2%
↑Gross Margin
71.6%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+63.8%
FCF CAGR
—
FCF margin
-2.2%
FCF / Net income
-0.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $782.5M · net income $100.3M · FCF $-17.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $782.5M | $782.5M | $527.8M | $334.1M | $177.9M |
| Net Income | $100.3M | $100.3M | $-78.7M | $-113.6M | $-199.7M |
| EBITDA | $140.3M | $140.3M | $-41.6M | $-86.6M | $-186.0M |
| EPS | 0.31 | 0.31 | -0.24 | -0.34 | — |
| Gross Margin | 71.6% | 71.6% | 72.9% | 75.6% | 74.1% |
| Operating Margin | 9.8% | 9.8% | -27.3% | -66.5% | -122.7% |
| Net Margin | 12.8% | 12.8% | -14.9% | -34.0% | -112.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.00 | 0.00 |
| Current Ratio | 5.98 | 5.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-17.3M | $-17.3M | $-92.5M | $-236.6M | $-205.8M |
| Returns | |||||
| ROE | 3.2% | 3.2% | -2.6% | -3.7% | -6.4% |
| Valuation | |||||
| P/E | 23.26 | 23.26 | — | — | — |
| EV/EBITDA | 44.99 | 44.99 | — | — | — |
| P/B | 2.14 | 2.14 | 1.29 | 1.41 | 2.54 |
| Growth & Yield | |||||
| Revenue Growth | 48.3% | 48.3% | 58.0% | 87.8% | — |
| EPS Growth | 227.4% | 227.4% | 29.4% | — | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
80.4%
EPS terminal req.
$1.80
Spread vs growth
146.9%
5Y implied EPS CAGR
48.0%
EPS terminal req.
$2.17
Spread vs growth
179.3%
10Y implied EPS CAGR
27.6%
EPS terminal req.
$3.50
Spread vs growth
199.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.24 → 0.31
Residual
+4.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.